NIH entrusted our team with conducting a research initiative to explore variations in bending stiffness and strength based on fiber diameter. The objective was to understand the relationships between these critical properties and fiber diameter, which is paramount for developing and optimizing pharmaceutical products.
We determined the sample size using a robust power analysis to ensure precision. We specified the anticipated effect size, significance level (alpha), and desired power (1—beta) parameters.
The foundation of this research project was a massive dataset comprising survey responses from 12,000 patients collected over six years, providing a robust platform for examining the differences in bending stiffness and strength based on fiber diameter.
The research’s central hypothesis was H1—There are significant differences in bending stiffness and strength based on fiber diameter. We used Multivariate Analysis of Variance (MANOVA) using SAS to test this hypothesis rigorously.
The analysis yielded compelling findings that provided valuable insights into Johnson & Johnson’s inquiry. The research results confirmed the presence of statistically significant differences in bending stiffness and bending strength based on variations in fiber diameter. These findings underscored the importance of fiber diameter as a critical factor influencing the mechanical properties of pharmaceutical products.
NIH derived valuable insights from this research endeavor. By confirming the significant differences in bending stiffness and strength based on fiber diameter, NIH gained a deeper understanding of the impact of fiber characteristics on pharmaceutical product properties. This knowledge informed the development and optimization of pharmaceutical formulations.